JP Morgan 44th Annual Healthcare Conference

January 13, 2026

HAEMONETICS®

Important Information

Safe Harbor for Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements do not relate strictly to historical or current facts and may be identified by the use of words such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “forecasts,” “foresees,” “potential” and other words of similar meaning in conjunction with statements regarding, among other things, (i) plans and objectives of management for operations of Haemonetics Corporation (“Haemonetics” or the “Company”), including plans or objectives related to the Company’s strategy for growth; product development, commercialization and anticipated benefits; regulatory approvals; the impact of acquisitions and divestitures; market position and expenditures; and the Company’s market and regional alignment initiative; (ii) estimates or projections of future financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the Company’s share repurchase program; and (iii) the assumptions underlying or relating to any statement described in points (i) and (ii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties.

Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results can be found in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed or to be filed with the U.S. Securities Exchange Commission (the “SEC”) under the headings “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Information” and in the Company’s other periodic filings with the SEC. The Company does not undertake to update these forward-looking statements.

Non-GAAP Financial Measures

This presentation contains non-GAAP financial measures as defined under applicable SEC rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with U.S. GAAP. We strongly encourage investors to review the Company’s financial statements and publicly-filed reports in their entirety and not rely on any single financial measure. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies. To the extent available without unreasonable effort, we have provided reconciliations of these non-GAAP measures to their most comparable GAAP measure in the appendix to this presentation, which is available on our website at www.haemonetics.com. With the exception of fiscal 2026 revenue guidance, the Company does not provide a reconciliation of forward-looking non-GAAP measures because certain significant information necessary for such reconciliations are unavailable, dependent on future events outside of our control and cannot be predicted without unreasonable efforts.

When used in this release, organic revenue growth excludes the impact of currency fluctuation, acquisitions and divestitures. Organic ex-CSL revenue growth further excludes the impact of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company. Adjusted operating income, adjusted provision for income taxes, adjusted net income and adjusted earnings per diluted share exclude restructuring costs, restructuring related costs, digital transformation costs, amortization of acquired intangible assets, asset impairments and write downs, amortization of fair value inventory step-up, costs related to compliance with the European Union Medical Device Regulation and In Vitro Diagnostic Regulation, acquisition, integration and divestiture related costs, net gains on the repurchase of convertible notes, gains on sales of property, plant and equipment, certain tax settlements, unusual or infrequent and material litigation-related charges, and remeasurement of contingent consideration liability. Adjusted earnings per diluted share also exclude the tax impact of these items. The adjustments to provision for income taxes are calculated based on the jurisdictions in which pre-tax adjustments occurred. Free cash flow is defined as cash provided by operating activities less capital expenditures and additions to Haemonetics equipment, net of the proceeds from the sale of property, plant and equipment.

Haemonetics at a Glance

FY'25 REVENUE

22.7%
Blood Management Technologies

18.8%
Interventional Technologies





HAE
NYSE ticker

~$4.0B
Market Cap[1]

3000+
employees

1) Market capitalization as of January 12, 2026.

HAEMONETICS®

FY’23 – FY’26 Transformational Growth

CORPORATE STRATEGY

Compete in winning segments and geographies

Achieve leading positions

Deliver superior operating performance

GOALS

GROWTH

Revenue **Profitability** **Cash Flow**

DIVERSIFICATION

- Business Segments
- Customers
- Geographies
- Business Models

SUSTAINABILITY

- Economic
- People
- Societal
- Environmental

HAEMONETICS®

A Durable, High-Return Model Built to Compound Value

Attractive business model & leading share across three main growth products



of revenue is recurring[4]

FY'22-FY'26E[1]

~8%
Revenue CAGR

~13%
Organic revenue CAGR ex. CSL

+~770bps
In adjusted operating margins

~17%
Adjusted EPS CAGR

Quality earnings and strong balance sheet

92%
FCF conversion ratio[2]

Up to **$1B** in capital capacity available for value creation[3]

1) Based on the mid-point of the Company's FY'26 guidance issued on November 6, 2025. 2) Free cash flow to adjusted net income conversion ratio for the twelve trailing months as of Q2 FY'26. 3) Capital capacity is calculated as total cash plus available borrowings under the Company's revolving credit facility up to a maximum consolidated net leverage ratio of 4.5X EBITDA. 4)Recurring revenue includes single-use disposables and software.

HAEMONETICS®

Portfolio Transformation Laying the Foundation for Sustainable Growth



High growth portfolio: mid single-digit to double-digit growth

- Plasma
- Blood Management Technologies
- Interventional Technologies

Legacy portfolio: low single-digit decline to flat

- Blood Center (ongoing rationalization)

1) Portfolio transitions include the impact of approximately $100M in fiscal 2025 U.S. disposables sales to CSL Plasma, $49M relating to the divestiture of the Whole Blood product line in January 2025, and the exit of certain liquids solution products. 2) Based on the mid-point of the Company's FY'26 guidance issued on November 6, 2025.

HAEMONETICS®

Three Core Products With Leading Positions Driving Nearly All Revenue Growth

Plasma

FY'25 Revenue

#1

in plasma collections with **NexSys PCS®**

Blood Management Technologies

FY'25 Revenue



#1

in viscoelastic testing with **TEG®6s** (Hemostasis Management)

Interventional Technologies

FY'25 Revenue



#1

in electrophysiology with **VASCADE MVP®** (Vascular Closure)

HAEMONETICS®

Driving Sustained Market Leadership with Industry-Defining Plasma Innovation

PLASMA MARKET

~$1B SAM[1]

growing MSD-HSD



PLASMA SAM GROWTH DRIVERS:

Demand for Immunoglobulins (Ig):

- PID, SID, Others[2]

Mature, growing market

~50% Global HAE share[3]

The only provider of fully integrated plasma collection solutions focused on reducing Cost Per Liter (CPL)

DELIVERING UNRIVALED PLASMA CENTER CAPABILITIES

1. Yield
2. Productivity
3. Safety
4. Donor Experience



DRIVERS OF REVENUE GROWTH

Growth in plasma collections	Global market share expansion	Innovation focused on top customer KPI's

1) Serviceable Addressable Market (SAM) is calculated as total plasma collections (excluding China) in fiscal year 2025 multiplied by the average selling price of Haemonetics' total product offerings in each geography. [US plasma collections data is from PPTA, Europe & ROW collections data is from the "Global Blood & Plasma Collections and Use 2023/2024" report by MRB, Sep. 2025.] 2) Primary immunodeficiency (PID), Secondary immunodeficiency (SID), and Others include Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Immune Thrombocytopenic Purpura (ITP), and Myasthenia gravis (MG). 3) Global HAE share as of the fiscal year 2025 end.

HAEMONETICS®

Building Momentum and Making TEG® 6s the Standard for Viscoelastic Testing

VISCOELASTIC TESTING (VET) MARKET

~$420M SAM[1]

growing MSD





VET SAM GROWTH DRIVERS:

Growth in trauma and cardiac procedures

Developing market with a penetration rate of ~60%

~45% HAE share[2]

TEG® 6s is the only integrated VET system, and the only system offering PlateletMapping® functionality

TEG® 6s

TEG Manager® software

Real-time, **actionable insight** into coagulation status enabling clinicians to make **rapid, targeted treatment decisions, improving patient outcomes** while **reducing costs** and **risks** of unnecessary transfusions.

DRIVERS OF REVENUE GROWTH

Penetration in the top 700 accounts in the US; international expansion

Legacy TEG® 5000 device upgrade cycle

Pipeline of innovation
- Clinical segments
- Product portfolio

1) Serviceable Addressable Market reflects existing commercial geographies and indications. Data sources include iData, DRG/Clarivate, MedTech Insight, and internal Company estimates. Includes the Top 7 geographies multiplied by average test utilization and average selling price in each geography. 2) Global HAE share of the total SAM in FY'25.

HAEMONETICS®

Expanding Market and Growth Momentum in Electrophysiology with Vascular Closure

ELECTROPHYSIOLOGY MARKET

~$600M SAM[1]

growing MSD - HSD



US EP SAM[2]



EP MARKET GROWTH DRIVERS:

Growth in LAAC and Afib procedures

Developing market with a penetration rate of ~60% (US)

~40% US HAE share[5]

Robust clinical evidence[3] supporting continued adoption and market share leadership in EP

Simple-to-use resorbable collagen plug that expands to fill the tissue track

64% reduction in median time to ambulation

63% Improvement in patient satisfaction[4]

58% Reduction in opioid Use



DRIVERS OF REVENUE GROWTH

Penetration into the Top 600 accounts in the US; international expansion

Increase in the utilization of existing accounts

Pipeline of innovation
- Clinical segments
- Product portfolio

1) Serviceable Addressable Market reflects existing commercial geographies and is calculated as total procedure volumes multiplied by average selling price by region. Procedure data sourced from Clarivate and MRB. 2) Afib – Atrial Fibrillation ablation, LAAC - Left Atrial Appendage Closure, VT – Ventricular Tachycardia ablation, SVT – Supraventricular Tachycardia, FL – Atrial Flutter. 3) As demonstrated in the AMBULATE pivotal trial, compared to manual compression. 4) Patient satisfaction data on a scale of 0-10, with 0 being the worst and 10 being the best. 5) HAE share of the US SAM.

HAEMONETICS®

Acquisition of Vivasure Unlocks Attractive TAM and Secures Category Leadership in Closure

ACQUISITION SUMMARY

- Up to €185M in total purchase price
- $300M attractive and growing TAM[1]

STRONG CLINICAL ADVANTAGES

- Fully absorbable sutureless design with no need to pre-close.
- 0% major complications through 30-day follow-up[2]
- Immediate median time to hemostasis[3]

Category Leadership in Vascular Closure from 5F up to 22F in ID (up to 26F in OD)



VASCADE®

5F 7F

Sheath Femoral Arterial and Venous Closure System

VASCADE MVP®

6F 12F

Sheath Femoral Venous Closure System (up to 15F OD)

VASCADE MVP® XL

10F 12F 14F

Sheath Femoral Venous Closure System (up to 17F OD[4])

PerQseal® Elite[5]

14F 22F

Sheath Femoral Arterial and Venous Closure System (up to 26F OD)

1) Addressable procedures multiplied by ASP. 2) Results from the prospective, single-arm, multi-center ELITE study; N=106 arterial per-protocol subjects, access site device-related vascular complications per VARC-3 definition. 3) Results from the prospective, single-arm, multi-center ELITE study; N=109 arterial, per-protocol closures. 4) Vascade MVP® XL is pending FDA approval for label expansion up to 17F OD. 5) PerQseal Elite is available for sale in the EU; Not available for sale in the US, pending PMA approval for arterial indication.

HAEMONETICS®

A Track Record of Improving Profitability and Free Cash Flow

Adjusted Operating Margin %

+~770bps



Adjusted EPS

~17% CAGR



Free Cash Flow

~2.5X



1) The mid-point of the Company's FY'26 guidance issued on November 6, 2025.

HAEMONETICS®

Value-Enhancing Capital Allocation

A relentless focus on **shareholder value creation**

ROIC increases from ~6.7% in FY'22 to **~11%** in Q2 YTD FY'26[1]

Consistent **strong cash generation** creates **optionality for capital deployment**



1) Please refer to Appendix E for the ROIC formula

HAEMONETICS®

Appendices

Appendix A: Reconciliation of GAAP Revenue to Organic Revenue, ex CSL Compounded Annual Growth Rate (CAGR)

($ millions)	FY 2026[2]	FY 2022	
	Mid-point of guidance	Actual	CAGR
Revenue	~ $1,326.8	$993.2	7.5%
Acquisitions and Divestitures[1]	~($48.1)	($76.4)	
CSL US Disposables	–	($102.4)	
Currency Impact	~($16.8)	($45.4)	
Organic Revenue, ex.CSL	~$1,261.9	$769.0	13.2%

1) Reflects revenue related to the Attune Medical, OpSens Inc. acquisitions and the divestiture of the Whole Blood business. 2) The mid-point of the Company's FY'26 guidance issued on November 6, 2025.

Appendix B: Reconciliation of GAAP to Non-GAAP Fiscal 2025 Financial Results

($ millions)	Gross profit	Operating expenses	Operating income (loss)	Interest and other expense	Provision (benefit) for income taxes	Net income (loss)	Earnings per diluted share
Reported	$749.0	$527.1	$221.8	($9.7)	$44.4	$167.7	$3.31
Amortization of acquired intangible assets	–	($48.3)	$48.3	–	$12.0	$36.3	$0.72
Amortization of fair value inventory step up	$15.0	–	$15.0	–	$3.6	$11.3	$0.22
Acquisition, integration and divestiture related costs	$3.2	($19.7)	$22.9	($2.5)	$2.4	$18.0	$0.35
Restructuring costs	$11.3	($2.6)	$13.9	–	$3.5	$10.4	$0.21
Restructuring related costs	$3.3	($3.9)	$7.2	–	$1.7	$5.6	$0.11
Digital transformation costs	–	($20.3)	$20.3	–	$4.8	$15.5	$0.30
Write downs of certain assets	–	($4.0)	$4.0	–	$1.0	$3.0	$0.06
MDR and IVDR costs	–	($4.8)	$4.8	–	$1.1	$3.7	$0.07
Litigation-related charges	–	($2.9)	$2.9	–	$0.7	$2.2	$0.04
Gain on repurchase of convertible notes, net	–	–	–	($12.6)	($3.1)	($9.5)	($0.19)
Gain on sale of property, plant and equipment	–	$14.1	($14.1)	–	($3.4)	($10.7)	($0.21)
Impairment of intangible assets	–	($2.4)	$2.4	–	$0.6	$1.8	$0.04
Remeasurement of contingent consideration	–	$23.0	($23.0)	–	($0.1)	($23.0)	($0.45)
Discrete tax items	–	–	–	–	$0.7	($0.7)	($0.01)
Adjusted	$781.8	$455.5	$326.3	($24.8)	$70.0	$231.5	$4.57
Adjusted, as a percentage of net revenues	57.4%	33.5%	24.0%			17.0%	

Appendix B: Reconciliation of GAAP to Non-GAAP Fiscal 2024 Financial Results

($ millions)	Gross profit	Operating expenses	Operating income (loss)	Interest and other expense	Provision (benefit) for income taxes	Net income (loss)	Earnings per diluted share
Reported	$691.5	$526.7	$164.9	($13.0)	$34.3	$117.6	$2.29
Amortization of acquired intangible assets	–	($32.0)	$32.0	–	$8.2	$23.8	$0.46
Amortization of fair value inventory step up	$3.3	–	$3.3	–	$0.9	$2.5	$0.05
Acquisition, integration and divestiture related costs	–	($11.2)	$11.2	–	$1.3	$9.9	$0.19
Restructuring costs	$11.3	($2.8)	$14.1	–	$3.2	$10.9	$0.21
Restructuring related costs	$5.7	($3.8)	$9.5	–	$2.4	$7.1	$0.14
Digital transformation costs	–	($15.7)	$15.7	–	$3.9	$11.8	$0.23
PCS2 related charges	$0.3	($4.8)	$5.1	–	$1.3	$3.8	$0.07
MDR and IVDR costs	–	($5.6)	$5.6	–	$1.3	$4.3	$0.08
Litigation-related charges	–	($6.7)	$6.7	–	$1.7	$5.0	$0.10
Impairment of intangible assets	–	($10.4)	$10.4	–	$3.4	$7.0	$0.14
Gain on divestiture	–	$2.0	($2.0)	–	($0.5)	($1.5)	($0.03)
Discrete tax items	–	–	–	–	($1.5)	$1.5	$0.03
Adjusted	$712.3	$435.7	$276.5	($13.0)	$59.9	$203.6	$3.96
Adjusted, as a percentage of net revenues	54.4%	33.3%	21.1%			15.6%	

Appendix B: Reconciliation of GAAP to Non-GAAP Fiscal 2023 Financial Results

($ millions)	Gross profit	Operating expenses	Operating income (loss)	Interest and other expense	Provision (benefit) for income taxes	Net income (loss)	Earnings per diluted share
Reported	$615.1	$459.1	$156.0	($14.6)	$26.0	$115.4	$2.24
Amortization of acquired intangible assets	–	($32.6)	$32.6	–	$10.0	$22.7	$0.44
Integration and transaction costs	–	$0.4	($0.4)	–	($0.1)	($0.3)	($0.01)
Restructuring costs	($0.2)	($0.9)	$0.7	–	$0.2	$0.5	$0.01
Restructuring related costs	$8.0	($2.9)	$10.9	–	$3.1	$7.8	$0.16
Digital transformation costs	–	($4.5)	$4.5	–	$1.6	$3.0	$0.06
Write downs of certain in-process intangible assets and PCS2 related charges	($1.0)	($0.4)	($0.6)	–	($0.2)	($0.4)	($0.01)
MDR and IVDR costs	$0.1	($9.8)	$9.9	–	$2.8	$7.1	$0.14
Litigation-related charges	–	($5.2)	$5.2	–	$1.8	$3.5	$0.07
Gain on sale of assets	–	$0.4	($0.4)	–	($0.1)	($0.3)	($0.01)
Discrete tax adjustments	–	–	–	–	$3.2	($3.2)	($0.06)
Adjusted	$622.0	$403.6	$218.4	($14.6)	$48.1	$155.7	$3.03
Adjusted, as a percentage of net revenues	53.2%	34.5%	18.7%			13.3%	

Appendix B: Reconciliation of GAAP to Non-GAAP Fiscal 2022 Financial Results

($ millions)	Gross profit	Operating expenses	Operating income (loss)	Interest and other expense	Provision (benefit) for income taxes	Net income (loss)	Earnings per diluted share
Reported	$505.5	$424.8	$80.8	($17.1)	$20.3	$43.4	$0.84
Amortization of acquired intangible assets	–	($47.4)	$47.4	–	$9.7	$37.7	$0.73
Integration and transaction costs	$5.3	($16.3)	$21.6	–	$4.5	$17.1	$0.33
Restructuring costs	$2.2	($2.0)	$4.2	–	$0.5	$3.7	$0.07
Restructuring related costs	$17.8	($6.8)	$24.6	–	$5.2	$19.4	$0.38
Impairment of assets and PCS2 related charges	$4.9	($0.9)	$5.7	–	$1.2	$4.5	$0.09
MDR and IVDR costs	–	($11.0)	$11.0	–	$2.3	$8.7	$0.17
Litigation-related charges	–	($1.4)	$1.4	–	$0.3	$1.1	$0.02
Gain on divestiture	–	$9.6	($9.6)	–	($2.0)	($7.6)	($0.15)
Discrete tax adjustments	–	–	–	–	($4.6)	$4.6	$0.10
Adjusted	$535.7	$348.6	$187.1	($17.1)	$37.4	$132.6	$2.58
Adjusted, as a percentage of net revenues	53.9%	35.1%	18.8%			13.3%	

Appendix C: Reconciliation of Cash Flows

($ millions)	FY 2025	FY 2024	FY 2023	FY 2022
Free Cash Flow Reconciliation				
Cash provided by operating activities	$181.7	$181.7	$273.1	$172.3
Capital expenditures	($39.3)	($38.1)	($29.1)	($44.7)
Additions to Haemonetics' equipment	($21.1)	($28.2)	($81.1)	($51.8)
Proceeds from sale of property, plant and equipment	$23.3	$1.8	$1.6	$2.0
Free cash flow	$144.6	$117.3	$164.5	$77.8

Appendix D: Fiscal 2026 Guidance

GAAP Revenue and Organic Revenue Growth Guidance

	Plasma	Blood Center	Hospital	Total Company
Reported	**(4–7%)**	**(17–19%)**	**4–7%**	**(1–4%)**
Currency Impact	–	1%	–	1%
Acquisitions & Divestitures[1]	–	(19%)	–	(4%)
Organic	**(4–7%)**	**(1)–1%**	**4–7%**	**(1)–2%**
CSL 2025 US disposables revenue[2]	21%	–	–	8%
Organic, ex-CSL	**14–17%**	**(1)–1%**	**4–7%**	**7–10%**

Adjusted Operating Margin, Earnings per Share and Free Cash Flow Guidance

	Total Company
Adjusted operating margin	26–27%
Adjusted earnings per diluted share	$4.80–$5.00
Free cash flow	$170M–$210M
Free cash flow to adjusted net income	>70%

1) Reflects adjustment in Blood Center to exclude the impact of the Company's divestiture of its Whole Blood product line in January 2025 and exit of certain liquid solution products. 2) Reflects adjustment to exclude the impact of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company.

Appendix E: ROIC formula

HAEMONETICS®